Crohn Disease
Conditions
Brief summary
Stem cell transplantation has emerged as a relatively popular treatment that can help to regulate immunity, repair injury, and control inflammation. Several studies have used autologous stem cells or adipose-derived stem cells to treat Crohn's disease and its associated complications, and have achieved good efficacy. Thus far, the use of umbilical cord mesenchymal stem cells (UC-MSCs) to treat Crohn's disease has rarely been reported. In this study, UC-MSCs were used to treat patients with hormone-controlled Crohn's disease. We observed the disease control conditions, corticosteroid dosage changes, and treatment-related adverse reactions.
Interventions
OTHERUC-MSCs by peripheral intravenous infusion
DRUGreceived hormone maintenance therapy
Sponsors
Shaanxi Provincial People's Hospital
Fuzhou General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* above 18 years of age * moderate to severe Crohn's disease (Crohn's disease activity index (CDAI) between 220 and 450) * had received hormone maintenance therapy for more than 6 months
Exclusion criteria
* active tuberculosis * malignancy * HIV * syphilis * hepatitis B * hepatitis C
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Crohn's disease activity index | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Harvey-Bradshaw index | 12 months |
| Corticosteroid dosage | 12 months |
Countries
China
Outcome results
None listed